PA-BENTLEY-SYSTEMS
9.7.2020 15:33:09 CEST | Business Wire | Press release
Bentley Systems, Incorporated, a leading global provider of comprehensive software and digital twins services for advancing the design, construction, and operations of infrastructure, today announced that its Acceleration Fund has invested in launching Virtuosity , a Bentley company. Virtuosity exclusively offers Virtuoso Subscriptions that bundle — with a Bentley infrastructure modeling, simulation, or construction application — the virtually delivered services of Virtuosity’s experts to accelerate and advance the success of an infrastructure practitioner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005552/en/
Virtuoso Subscriptions are now available, at virtuosity.com , for Bentley applications including MicroStation , OpenBridge , OpenBuildings , OpenFlows , OpenRail , OpenRoads , OpenSite , OpenTower , OpenWindPower , AutoPIPE , ContextCapture , LEGION , MOSES , PLAXIS , RAM , SACS , SoilVision , STAAD , and SYNCHRO , and Bentley’s iTwin Design Review cloud service. Virtuosity’s expert services, accessible through Virtuoso Subscription “keys,” include a range of training and one-to-one mentoring activities, and on-demand learning and content, increasingly integrated during actual application usage.
Allan Murphy, Virtuosity CEO, said, “The world’s infrastructure professionals have all gained a new appreciation for what can be achieved through online collaboration. We think this is the perfect time to inaugurate our commercial innovation: a virtuoso subscription that enhances the functionality of a software application through intrinsic assistance from subject matter experts. We’re marshalling and virtualizing our domain expertise to help every infrastructure practitioner perform with the confidence of a virtuoso!”
Werner Felber, Managing Partner, Boley Geotechnick GmbH, Beratende Ingenieure, said, “With Virtuoso Subscriptions, professionals across our international teams can support projects more effectively. Virtuosity’s experts will help keep us current in going digital by constantly leveraging what’s new in Bentley’s applications to ensure our competitiveness in the market and the best results for our customers.”
Image: Virtuosity logo
Image: Allan Murphy headshot
YouTube video: The Value of a Virtuoso Subscription
About Virtuosity, a Bentley Company
Virtuosity
is the exclusive global provider of Virtuoso Subscriptions
for Bentley Systems’ infrastructure modeling, simulation, and construction applications. Every Virtuoso Subscription—procured through the ecommerce site virtuosity.com
—uniquely bundles, with a Bentley software application, virtually delivered services of Virtuosity’s experts to accelerate and advance the success of an infrastructure practitioner.
About Bentley Systems’ Acceleration Fund
Bentley Systems’ Acceleration Fund was founded in 2020 to invest in new and incremental participants in open ecosystems to advance infrastructure digital twins. The Bentley Systems Acceleration Fund is chartered to accelerate the creation and curation of digital twins, and to foster technologies and innovations so enabled, by nurturing new ventures, making minority investments, and acquiring and expanding digital integrators. Investments to date include Digital Water Works, Digital Construction Works, Virtuosity, and The Cohesive Companies. Chief Acceleration Officer Santanu Das welcomes queries from potential ecosystem participants at www.bentleyaccelerationfund.com
.
About Bentley Systems
Bentley Systems is a leading global provider of software solutions to engineers, architects, geospatial professionals, constructors, and owner-operators for the design, construction, and operations of infrastructure. Bentley’s MicroStation
-based engineering and BIM applications, and its digital twin cloud services, advance the project delivery (ProjectWise
) and the asset performance (AssetWise
) of transportation and other public works, utilities, industrial and resources plants, and commercial and institutional facilities.
Bentley Systems employs more than 3,500 colleagues and generates annual revenues of more than $700 million in 172 countries. From inception in 1984, the company has remained majority-owned by its five founding Bentley brothers. www.bentley.com
Bentley, the Bentley logo, Bentley Acceleration Fund, AssetWise, AutoPIPE, ContextCapture, iTwin, LEGION, MicroStation, MOSES, OpenBridge, OpenBuildings, OpenFlows, OpenRail, OpenRoads, OpenSite, OpenTower, OpenWindPower, PLAXIS, ProjectWise, RAM, SACS, SoilVision, STAAD, SYNCHRO, Digital Water Works, The Cohesive Companies, Virtuosity, and Virtuoso Subscription are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005552/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom